New England journal of medicine
32 articles tagged "New England journal of medicine"
← Across Medicine
Mim8 Prophylaxis Reduces Bleeding in Hemophilia A with or without Inhibitors
Phase 3 data show weekly or monthly subcutaneous Mim8 significantly lowers bleeding rates compared to on-demand and prior factor therapy.
Pulsed Field Ablation Reduces Recurrence in Persistent Atrial Fibrillation
First-line pulsed field ablation showed a 56% success rate at 12 months compared to 30% for antiarrhythmic drugs in a randomized trial.
Balanced Fluids and Saline Show Similar Outcomes in Pediatric Septic Shock
A large trial of over 8,000 children found no difference in kidney events or mortality between balanced crystalloids and 0.9% saline.
Triple-Pill Therapy Reduces Recurrent Stroke Risk After Intracerebral Hemorrhage
A low-dose combination of telmisartan, amlodipine, and indapamide lowered systolic blood pressure and major cardiovascular events.
Ketamine Does Not Reduce 28-Day Mortality Compared With Etomidate
A randomized trial of 2,365 critically ill adults found no survival benefit for ketamine, despite a higher rate of cardiovascular collapse.
Nirmatrelvir-Ritonavir Fails to Reduce Hospitalization in Vaccinated Outpatients
Two randomized trials show no significant clinical benefit for high-risk adults with prior immunity from vaccination or infection.
Estradiol Patches Noninferior to LHRH Agonists in Prostate Cancer
A phase 3 trial shows transdermal estradiol maintains metastasis-free survival while reducing hot flashes in locally advanced disease.
Endovascular Therapy Eases Post-Thrombotic Syndrome but Increases Bleeding
Iliac-vein stenting with enhanced antithrombotics improves symptoms and quality of life at six months, despite a higher bleeding risk.
Routine Prednisolone Does Not Prevent Coronary Lesions in Kawasaki Disease
A large randomized trial shows that adding steroids to standard therapy does not protect the coronary arteries of unselected children.
Zongertinib Drives High Response in First-Line HER2-Mutant Lung Cancer
The selective HER2 inhibitor achieved a 76% objective response rate and durable progression-free survival in treatment-naive patients.
Asundexian Reduces Recurrent Stroke Without Increasing Major Bleeding
Adding the Factor XIa inhibitor asundexian to standard antiplatelet therapy safely lowers recurrent stroke risk in high-risk patients.
High-Flow Oxygen Lowers Intubation but Does Not Improve Survival
High-flow nasal cannula therapy reduces intubation rates in acute hypoxemic respiratory failure without altering 28-day mortality.